Serina Therapeutics, Inc. Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities
Serina Therapeutics, Inc. (SER) reported Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities of 0 shares for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-24.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities · last filed 2025-03-24
- Serina Therapeutics, Inc. incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2024-09-30 was 0.00 shares, a 100.00% decline year-over-year.
- Serina Therapeutics, Inc. incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2023-09-30 was 115.00K shares.
- Serina Therapeutics, Inc. incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2023-06-30 was 115.00K shares.
- Serina Therapeutics, Inc. incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2023-03-31 was 689.00K shares.
- Serina Therapeutics, Inc. incremental common shares attributable to dilutive effect of conversion of debt securities for fiscal 2024 was 0.00 shares.
- Serina Therapeutics, Inc. incremental common shares attributable to dilutive effect of conversion of debt securities for fiscal 2023 was 0.00 shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 3 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 6 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 9 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 12 month |
|---|---|---|---|---|
| 2024-12-31 | 0.00 shares 10-K · filed 2025-03-24 | |||
| 2024-09-30 | 0.00 shares 10-Q · filed 2024-11-12 | 0.00 shares 10-Q · filed 2024-11-12 | ||
| 2023-12-31 | 0.00 shares 10-K · filed 2025-03-24 | |||
| 2023-09-30 | 115.00K shares 10-Q · filed 2024-11-12 | 113.00K shares 10-Q · filed 2024-11-12 | ||
| 2023-06-30 | 115.00K shares 10-Q · filed 2024-08-09 | 113.00K shares 10-Q · filed 2024-08-09 | ||
| 2023-03-31 | 689.00K shares 10-Q · filed 2024-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| TALPHERA, INC. (TLPH) | United States | $0.060B |